Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Pathology are his primary areas of study. Survival rate, Amyloidosis, Transplantation, Primary systemic amyloidosis and Survival analysis are the subjects of his Internal medicine studies. His Multiple myeloma research includes themes of Monoclonal gammopathy of undetermined significance, Disease and Dexamethasone.
His Surgery research is multidisciplinary, incorporating perspectives in Clinical trial and Intensive care medicine. His research integrates issues of Progressive disease, Neutropenia, Chemotherapy and Myeloma protein in his study of Gastroenterology. The various areas that John A. Lust examines in his Pathology study include Chromosomal translocation, Neovascularization and Cytogenetics.
John A. Lust mostly deals with Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Pathology. He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Oncology and, in certain cases, Newly diagnosed and Clinical trial. His work carried out in the field of Multiple myeloma brings together such families of science as Monoclonal gammopathy of undetermined significance, Bone marrow, Transplantation and Cohort.
His work deals with themes such as Survival rate, Myeloma protein, Progression-free survival and Primary systemic amyloidosis, which intersect with Gastroenterology. His studies deal with areas such as Fluorescence in situ hybridization, Flow cytometry and Monoclonal as well as Pathology. His study in Lenalidomide is interdisciplinary in nature, drawing from both Neutropenia and Bortezomib.
John A. Lust focuses on Internal medicine, Multiple myeloma, Oncology, Gastroenterology and AL amyloidosis. His Internal medicine research focuses on Surgery and how it relates to Clinical trial. His work on Lenalidomide as part of general Multiple myeloma study is frequently linked to In patient, bridging the gap between disciplines.
His biological study spans a wide range of topics, including Hematopoietic stem cell transplantation and POEMS syndrome. The concepts of his Gastroenterology study are interwoven with issues in Creatinine, Monoclonal gammopathy of undetermined significance, Odds ratio and Progression-free survival. His work focuses on many connections between AL amyloidosis and other disciplines, such as Retrospective cohort study, that overlap with his field of interest in Multivariate analysis.
John A. Lust spends much of his time researching Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Surgery. He has researched Internal medicine in several fields, including Oncology and Pathology. His Multiple myeloma study combines topics from a wide range of disciplines, such as Clinical trial, Hematology, Hazard ratio, Confidence interval and Stage.
His Gastroenterology research includes elements of Odds ratio, Myeloma protein, Bone marrow and Monoclonal. His AL amyloidosis research is multidisciplinary, incorporating elements of Survival rate, Proteinuria and Urology. His Surgery course of study focuses on Bortezomib and Lenalidomide and Macroglobulinemia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle;Morie A. Gertz;Thomas E. Witzig;John A. Lust.
Mayo Clinic Proceedings (2003)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy.
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz.
POEMS syndrome: definitions and long-term outcome.
Angela Dispenzieri;Robert A. Kyle;Martha Q. Lacy;S. Vincent Rajkumar.
A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine
Robert A. Kyle;Morie A. Gertz;Philip R. Greipp;Thomas E. Witzig.
The New England Journal of Medicine (1997)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri.
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Angela Dispenzieri;Morie A. Gertz;Robert A. Kyle;Martha Q. Lacy.
Journal of Clinical Oncology (2004)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar;Angela Dispenzieri;Martha Q. Lacy;Suzanne R. Hayman.
Journal of Clinical Oncology (2012)
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
S. Vincent Rajkumar;Suzanne Hayman;Morie A. Gertz;Angela Dispenzieri.
Journal of Clinical Oncology (2002)
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
John A. Lust;Kathleen A. Donovan;Michael P. Kline;Philip R. Greipp.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: